APGE - Apogee Therapeutics, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 6 days)
EPS Est: $-1.05
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$108.86
DETAILS
HIGH:
$137.00
LOW:
$83.00
MEDIAN:
$103.00
CONSENSUS:
$108.86
UPSIDE:
52.74%
Market Cap:
3.91B
Volume:
557,717
Avg Volume:
986,015
52 Week Range:
26.2-84.56
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.43
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
196
IPO Date:
2023-07-14
EPS (TTM):
-3.30
P/E Ratio:
-13.73
Revenue (TTM):
N/A
Total Assets:
753.95M
Total Debt:
11.83M
Cash & Equiv:
141.79M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-29.9%
Debt/Equity:
0.02
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-1.11 | $-1.12 | +0.9% | — | — | — |
| 2025-08-11 | $-1.13 | $-1.03 | -9.7% | — | — | — |
| 2025-05-12 | $-0.95 | $-1.19 | +20.2% | — | — | — |
| 2025-03-03 | $-1.19 | $-0.94 | -26.6% | — | — | — |
| 2024-11-12 | $-0.86 | $-0.88 | +2.2% | — | — | — |
| 2024-08-12 | $-0.60 | $-0.64 | +6.3% | — | — | — |
| 2024-05-13 | $-0.64 | $-0.60 | -6.7% | — | — | — |
| 2024-03-05 | $-0.32 | $-0.45 | +28.9% | — | — | — |
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Net Income | (182.15M) | (83.98M) | (39.78M) |
| EPS | -3.30 | -1.66 | -0.79 |
| Total Assets | 753.95M | 401.40M | 152.06M |
| Total Debt | 11.83M | 2.03M | 0 |
| Cash & Equivalents | 141.79M | 118.32M | 151.89M |
| Operating Cash Flow | (171.17M) | (74.76M) | (16.43M) |
| Free Cash Flow | (172.33M) | (74.93M) | (16.43M) |
| FCF per Share | -3.12 | -1.48 | -0.32 |
| Book Value | 716.79M | 379.91M | 142.07M |
| Cash & ST Investments | 520.65M | 395.46M | 151.89M |
| ROC Equity | -0.25 | -0.22 | -0.28 |